( AMEX:NNVC )

News from NanoViricides, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

May 14, 2018, 11:28 ET NanoViricides Provides Update, Says Company is Stable and is Moving Steadily towards Clinical Trials

NanoViricides, Inc. (the "Company") reports that it is financially sound and that its drug candidates in the HerpeCide™ program are moving towards...


Apr 09, 2018, 07:00 ET NanoViricides Reports Good Safety Profile of Topical Dermal Drug Candidates; Dr. Diwan, President, Will Present at the MicroCap Conference in New York City Today

NanoViricides, Inc. (the "Company") reports that its drug candidates in the HerpeCide™ program have been found to be safe based on multiple...


Mar 19, 2018, 11:12 ET NanoViricides Drug Candidates to be Tested in Animal Models of Dermal, Ocular and Genital Herpes Virus Infection at the University of Wisconsin

NanoViricides, Inc. (NYSE American: NNVC) (the "Company") has announced that it has expanded its in vivo testing agreement with the University of...


Feb 21, 2018, 07:00 ET NanoViricides Files Quarterly Report for Period Ending December 31, 2017

NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel...


Dec 06, 2017, 07:00 ET Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates

NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") reports that it has begun initial safety and toxicology evaluation of its optimized...


Nov 20, 2017, 07:00 ET NanoViricides Files Quarterly Report for Period Ending September 30, 2017

NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel...


Nov 06, 2017, 07:00 ET NanoViricides Provides Further Details on Its Herpes-Induced Acute Retinal Necrosis Animal Study to be Presented On November 10th at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology

NanoViricides, Inc. (NYSE American: NNVC) (the "Company") reports that Dr. Vivien Boniuk, Consultant in Ophthalmology at the Company, will present...


Oct 26, 2017, 07:00 ET Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Center

NanoViricides, Inc. (NYSE American: NNVC (the "Company") announced today that it has extended its agreement with SUNY Upstate Medical Center for...


Oct 17, 2017, 07:00 ET NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology

NanoViricides, Inc. (NYSE American: NNVC) (the "Company") will present the results of its anti-herpes nanoviricide treatment for Viral Acute...


Sep 29, 2017, 07:30 ET NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials

NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), reports that it has filed its financial year end annual report (Form 10-K) with the...


Sep 11, 2017, 09:04 ET NanoViricides, Inc. Announces its CEO Dr. Seymour to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City on September 12, 2017

NanoViricides, Inc., (NYSE "NNVC") today announced it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global...


Jul 10, 2017, 07:00 ET NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin

NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") reports that its anti-shingles nanoviricides® drug candidates achieved dramatic reduction in...


Jun 26, 2017, 09:00 ET NanoViricides' Poster "Novel Nanoviricides® Highly Effective Against Varicella Zoster Virus in Cell Culture" to be Presented Today at the 2017 Annual Meeting of American Society of Virology

NanoViricides, Inc., (NYSE MKT: NNVC) (the "Company"), a pioneer in developing anti-viral nanomedicine drugs, is pleased to announce that its...


Jun 20, 2017, 07:00 ET NanoViricides Abstract Accepted for Poster Presentation at the 2017 Annual Meeting of American Society of Virology

NanoViricides, Inc., (NYSE MKT: NNVC) (the "Company"), a pioneer in developing anti-viral nanomedicine drugs, is pleased to announce that...


Jun 13, 2017, 07:00 ET NanoViricides CEO to Present Information on Its Topical Shingles Treatment At the 2017 Marcum Investor Conference in New York City

NanoViricides, Inc., (NYSE MKT: NNVC) (the "Company"), a pioneer in developing anti-viral nanomedicine drugs, reports that its CEO, Eugene Seymour,...


Jun 06, 2017, 17:30 ET NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell Culture Studies

NanoViricides, Inc., (NYSE MKT: NNVC) (the "Company"), a pioneer in developing anti-viral nanomedicine drugs, reports that its topical drug...


May 16, 2017, 07:50 ET NanoViricides Files Quarterly Report for Period Ending 2017-03-31

NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), filed the quarterly report for its third quarter of financial year 2017 in a timely manner...


Apr 26, 2017, 17:00 ET NanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 in Las Vegas; Company Says it is Close to Declaring a Clinical Candidate for the Treatment of Shingles

NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), reports that Eugene Seymour, MD, MPH, CEO, will present information about the Company and its...


Feb 16, 2017, 07:00 ET NanoViricides Files Quarterly Report for Period Ending 2016-12-31

NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), filed its quarterly report for its second quarter of financial year 2017 in a timely manner...


Feb 13, 2017, 07:00 ET NanoViricides Reports the Company's Director Dr. Boniuk Converted Series B Debenture to Equity Effectively Raising $5M in New Equity for the Company

NanoViricides, Inc. (NYSE MKT: NNVC), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines...


Dec 01, 2016, 07:00 ET NanoViricides Publishes a Letter from the CEO to Shareholders on its Website

NanoViricides, Inc. (NYSE MKT: NNVC), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines...


Nov 15, 2016, 07:00 ET NanoViricides Files Quarterly Report for Period Ending 2016-09-30

NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), filed its quarterly report for its first quarter of financial year 2017 in a timely manner...


Nov 07, 2016, 07:00 ET NanoViricides President Dr. Diwan Gave Invited Talks on Regulatory Aspects of Nanomedicines

NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), reports that its President Dr. Anil Diwan was recently invited to participate in certain...


Oct 31, 2016, 07:00 ET NanoViricides Signs Agreement with SUNY Upstate Medical Center for Testing of Its Drug Candidates for the Treatment of Shingles

NanoViricides, Inc. (NYSE MKT: NNVC (the "Company") announced today that it has entered into an agreement with SUNY Upstate Medical University for...


Oct 11, 2016, 07:00 ET NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials

NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), reports that it has filed its financial year end annual report (Form 10-K) with the...